Cambrex Revenue and Competitors
Estimated Revenue & Valuation
- Cambrex's estimated annual revenue is currently $531M per year.
- Cambrex received $200.0M in venture funding in April 2007.
- Cambrex's estimated revenue per employee is $308,362
- Cambrex's total funding is $241.7M.
Employee Data
- Cambrex has 1722 Employees.
- Cambrex grew their employee count by -10% last year.
Cambrex's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Drug substance BU VP Sales and Business Development Europe/Asia | Reveal Email/Phone |
3 | VP, Finance - Drug Product | Reveal Email/Phone |
4 | VP, Facilities | Reveal Email/Phone |
5 | VP and GM at Cambrex | Reveal Email/Phone |
6 | Head Solid State Science | Reveal Email/Phone |
7 | Quality Assurance Officer | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | Head Quality and Regulatory Compliance | Reveal Email/Phone |
10 | Vice Direttore di Produzione | Reveal Email/Phone |
Cambrex Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Cambrex?
Cambrex is an innovative life sciences company with a refreshingly human approach. Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers small molecule therapeutics into markets across the world. With over 35 years of active pharmaceutical ingredient (API) development and manufacturing expertise, a growing team of more than 1,200 experts and a strong presence in the USA and Europe, we are tried and trusted across branded and generic API markets. > We put all of our energy and experience into being your partner of choice > We create value for customers through manufacturing excellence, reliable quality and innovative science > Our people are the experts that our customers enjoy working with Our custom development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. We are committed to operating our facilities with the highest standards for regulatory, environmental, health, safety, and security guidelines. We actively incorporate Lean Six Sigma to consistently deliver efficient, high quality, and cost competitive products with less time to market for our clients. We are proud of our long history of regulatory excellence. When you work with Cambrex, you can expect a friendly, energetic and customer-focused team that will deliver your project requirements. And theyll do so with passion and integrity at the core. To experience the Cambrex difference, get in touch.
keywords:Biotechnology,Healthcare,Pharmaceuticals$241.7M
Total Funding
1722
Number of Employees
$531M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cambrex News
Cambrex has completed a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its...
Cambrex offers a range of specialized drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled...
Cambrex expands API manufacturing capacity at flagship US facility and Asymchem completes construction of two new Chinese API production...
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
CAMBREX INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $888.9M | 2797 | 6% | N/A |
Cambrex Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2001-11-30 | $430.0M | Credit Facility | Article | |
2004-08-03 | $0.0M | Title: President CEO | Article | |
2007-04-09 | $200.0M | Undisclosed | JPMorgan Chase Bank N.A | Article |